TB-500 Evidence Guide

Benefits and Evidence

• Wound Healing: Level B, includes human evidence - A Phase 2 RCT by RegeneRx (NCT00305838, Tβ4 topical gel RGN-137 for pressure ulcers) and a separate Phase 2 for venous stasis ulcers (NCT01307800) both showed numerical improvement over placebo but did not reach statistical significance on primary endpoints. The preclinical wound healing data is consistently positive across multiple independent labs (unlike BPC-157), which makes the human translational gap here more interpretable: it likely reflects dosing, formulation, or patient population issues rather than a false preclinical signal.
• Cardiac Repair: Level B, mostly non-human evidence - The 2004 Nature paper by Bock-Marquette et al. demonstrated that Tβ4 injected into mice after experimental MI reduced infarct size and improved ejection fraction. Smart et al. (Nature, 2007) extended this to epicardial progenitor mobilization. RegeneRx conducted a Phase 2 pilot (NCT00517543) for post-MI patients - the trial was underpowered for efficacy conclusions. No definitive human cardiac efficacy data exists.
• Anti-Inflammation: Level B, mostly non-human evidence - Consistent reduction of pro-inflammatory markers (TNF-α, IL-1β, NF-κB activity) across diverse injury models from multiple independent research groups. The anti-inflammatory mechanism is well-replicated; whether it translates to clinically meaningful effects in humans is untested outside of the wound/cardiac context.
• Hair Growth: Level C, mostly non-human evidence - Philp et al. (FASEB J, 2004) showed Tβ4 activation of hair follicle stem cells in mouse models, with increased hair growth. Evidence base is small and not independently replicated at sufficient scale for confident human extrapolation.
• Dry Eye / Corneal Healing: Level B, includes human evidence - RegeneRx's eye-drop formulation RGN-259 completed a Phase 2 trial for neurotrophic keratopathy (NCT02604966) and showed significant improvement in corneal sensitivity vs. placebo. This is the most positive human trial result for any Tβ4 formulation to date. A Phase 3 program has been explored, though development status is uncertain as of 2026.

Side Effects and Warnings

• Generally well-tolerated in clinical trials at doses up to 6 mg (RegeneRx Phase 2 data)
• Head rush or transient lightheadedness immediately post-injection (anecdotally reported, not systematically documented in trials)
• Mild injection site reactions (erythema, induration) at higher doses
• Transient lethargy in some users (anecdotal; not a documented finding in clinical trials)
• Not FDA-approved for any indication
• Banned by WADA under the category of peptide hormones, growth factors, and related substances - prohibited for all competitive athletes
• Theoretical concern: as a pro-angiogenic, pro-migratory peptide, Tβ4 could theoretically support tumor growth or metastasis - this risk has not been observed in clinical trials but has not been definitively excluded in long-term use
• Limited long-term human safety data (longest published trial approximately 6 months)

Research Dosage References

• <strong>Subcutaneous injection</strong> - 2-5 mg - Twice weekly (loading phase of 4-6 weeks), then 2-5 mg weekly (maintenance) - Derived from research community extrapolation rather than published human PK data. Loading/maintenance split is community convention, not an established clinical protocol.
• <strong>Intramuscular</strong> - 2-5 mg - Twice weekly - Used interchangeably with SC in most research contexts. Systemic distribution occurs regardless of injection site proximity to injury.

Mechanism of Action

TB-500's primary and best-characterized mechanism is G-actin sequestration: 1. G-actin sequestration and cell migration: The LKKTET motif (residues 17-23) of thymosin beta-4 binds monomeric G-actin with high affinity, preventing its spontaneous polymerization into F-actin filaments. This regulates cytoskeletal dynamics in a way that facilitates directed cell migration - particularly relevant for fibroblasts, endothelial cells, and stem cells migrating toward wound sites. This mechanism is well-established biochemically across multiple independent labs. 2. Integrin-linked kinase (ILK) activation: Bock-Marquette et al. (Nature, 2004) identified that Tβ4 activates ILK in cardiac progenitor cells independently of actin binding. ILK activation promotes cell survival, reduces apoptosis after ischemia, and supports cardiomyocyte migration. This cardiac pathway represents a mechanistically distinct action from the cytoskeletal effects. 3. Anti-inflammatory effects: Tβ4 downregulates NF-κB activity and reduces production of inflammatory cytokines including TNF-α and IL-1β. This has been demonstrated in multiple tissue injury models but the mechanism linking actin/ILK signaling to inflammatory suppression is not fully resolved. 4. Epicardial progenitor mobilization: Smart et al. (Nature, 2007) showed that Tβ4 primes adult epicardial cells to re-enter a progenitor state after MI, contributing to myocardial repair. This discovery was highly influential but the effect has proven difficult to translate to clinical benefit in the one completed cardiac trial. 5. Angiogenesis: Tβ4 promotes endothelial cell migration and tubule formation in vitro and increases vessel density in wound bed models, partly through VEGF upregulation.

Legal Status

TB-500 (synthetic thymosin beta-4) is not FDA-approved for any therapeutic use and cannot be legally marketed for human consumption in the United States. It is a research chemical. WADA prohibits Tβ4 under the Growth Factors and Related Substances section (S2) - athletes in tested sports should treat TB-500 as prohibited. Regulatory status varies internationally.

Primary Sources

1. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 2004.
2. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 2007.
3. Thymosin beta4 promotes dermal healing. Ann N Y Acad Sci, 2007.
4. Thymosin beta4 mobilizes hair follicle stem cells to undergo folliculogenesis in the mouse. FASEB J, 2004.
5. Phase 2 clinical trial of thymosin beta 4 eye drops (RGN-259) for neurotrophic keratopathy. Expert Opin Investig Drugs, 2018.
6. Actin-sequestering proteins and their involvement in wound healing and tissue repair. Trends Cell Biol, 2005.

Popular Questions

• TB-500 Benefits: Evidence, Verdict, and Limits
• TB-500 Side Effects: Safety Signals and Warnings
• TB-500 Research Dosage: Published Protocol Reference
• Is TB-500 Legit? Evidence Grade and Plain-English Verdict
• TB-500 Legal Status: Approval, Research Use, and Regulatory Notes

Related Peptides

• bpc-157
• ghk-cu
• ll-37